구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 21.15.GPC3-CAR T cells |
Overview Company | Baylor College of Medicine |
Overview Modality | CGT |
Overview Target | Hepatoblastoma |
Overview Indication | Hepatoblastoma; Hepatocellular Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
PK/PD Species | Mouse, Additionally |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Additionally |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | [Critical care management as part of oncological therapy].. With the global rise in cancer incidence, the number of critically ill oncology patients with potential need for intensive care unit (ICU) admission is also increasing. This trend is not solely attributable to disease progression, but also to the aging of the cancer population, often accompanied by significant comorbidities, and to compli… |
Toxicology CRS | Reported |
Clinical Safety signal | [Critical care management as part of oncological therapy].. With the global rise in cancer incidence, the number of critically ill oncology patients with potential need for intensive care unit (ICU) admission is also increasing. This trend is not solely attributable to disease progression, but also to the aging of the cancer population, often accompanied by significant comorbidities, and to compli… |
Clinical Program phase | PHASE_1 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 21.15.GPC3-CAR T cells |
Overview Company | Baylor College of Medicine |
Overview Modality | CGT |
Overview Target | Hepatoblastoma |
Overview Indication | Hepatoblastoma; Hepatocellular Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
PK/PD Species | Mouse, Additionally |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Additionally |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | [Critical care management as part of oncological therapy].. With the global rise in cancer incidence, the number of critically ill oncology patients with potential need for intensive care unit (ICU) admission is also increasing. This trend is not solely attributable to disease progression, but also to the aging of the cancer population, often accompanied by significant comorbidities, and to compli… |
Toxicology CRS | Reported |
Clinical Safety signal | [Critical care management as part of oncological therapy].. With the global rise in cancer incidence, the number of critically ill oncology patients with potential need for intensive care unit (ICU) admission is also increasing. This trend is not solely attributable to disease progression, but also to the aging of the cancer population, often accompanied by significant comorbidities, and to compli… |
Clinical Program phase | PHASE_1 |
추천 비교
추천 비교